{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/06/16/3312476/0/en/BioAge-Labs-Announces-First-Participant-Dosed-in-QUELL-CV-a-Phase-2-Proof-of-Concept-Trial-of-BGE-102-a-Novel-Oral-NLRP3-Inhibitor-in-Patients-at-Elevated-Cardiovascular-Risk.html", "message": "News view counter 801606 successfully enlarged"}